Alembic Pharmaceuticals gets USFDA nod for generic hypertension treatment capsules

Usa markets awards WhatsApp Food Iqvia Pharmaceuticals

11.11.2024 - 08:15

Reading now: 460

economictimes.indiatimes.com:

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of hypertension. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules of strengths 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, Alembic Pharmaceuticals Ltd (Alembic) said in a statement.
These capsules are indicated for the treatment of hypertension. These capsules may be used alone or in combination with other antihypertensive medications.
Moreover, Diltiazem Hydrochloride is also indicated for the management of chronic stable angina and angina due to coronary artery spasm, the company said.

Diltiazem Hydrochloride extended-release capsules 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of USD 105.3 million for the 12 months ended June 2024, the company said citing IQVIA data.

Nominations for ET MSME Awards are now open. The last day to apply is November 30, 2024. Click here to submit your entry for any one or more of the 22 categories and stand a chance to win a prestigious award.

(You can now subscribe to our Economic Times WhatsApp channel)
Read more on economictimes.indiatimes.com

All news from economictimes.indiatimes.com

About this in other media

Who is Mike Waltz, Donald Trump's national security advisor, and why is it good news for India but bad for China? economictimes.indiatimes.com /2 days ago

Polling Nostradamus Allan Lichtman gets death threats after predicting the 2024 U.S elections wrong; there were two break-in attempts on his home economictimes.indiatimes.com /2 days ago

Sterlite Power gets Rs 1,200 cr orders in Q2 economictimes.indiatimes.com /3 days ago

The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.